蔡振宇 - 同济大学

个人简介

蔡振宇教授主要从事坏死性凋亡的分子机制及其相关肿瘤和炎症性疾病的研究。入选青年海外高层次人才引进计划，获得科技部，国家自然科学基金，宁夏自治区重点研发计划及上海市科委等项目资助。近五年来，研究成果以通讯作者或第一作者发表在Nat Cell Biol, Cell Research，PNAS, Cancer Research, Br J Pharmacol, J Med Chem等杂志。其中2篇的研究论文入选ESI前1%高被引论文。申报国内专利4项。教育，工作简历 2020年6月—至今：教授，同济大学医学院/同济大学附属上海市第十人民医院 2017年2月—2020年5月：研究员，海军军医大学第三附属医院 2011年2月—2017年2月：访问学者 (Visiting Fellow)，美国国立卫生研究院 2006年9月—2010年12月：博士，生物医学，美国德州农工大学 2003年9月—2006年6月：硕士，遗传学，湖南师范大学 1999年9月—2003年6月：本科，生物技术，湖南师范大学

研究领域

细胞死亡与疾病我们主要研究坏死性细胞凋亡的分子机制及其在包括肿瘤等炎症相关性疾病中的作用。同时，我们课题组也致力于新型抗坏死性细胞凋亡药物发现与转化应用研究。坏死性凋亡与不可调控性细胞坏死表现相似的形态学特征，包括细胞肿胀、细胞膜破裂和细胞内容物释放等。由于细胞内容物的释放，坏死性细胞凋亡会引起体内大量炎症细胞浸润从而诱发严重的炎症反应。目前的研究表明，坏死性细胞凋亡作为新的一类细胞程序性死亡方式，在缺血性损伤、神经退行性疾病、恶性肿瘤、病毒感染和免疫性疾病等多种疾病的病理生理过程中起重要作用，发现其小分子抑制剂对于坏死性凋亡相关疾病的临床治疗具有十分重大的意义。本课题组主要研究方向：（1）抗坏死性凋亡小分子药物筛选、鉴定与临床应用（2）坏死性凋亡及其所诱发的炎症反应与肿瘤发生发展的关系（主要以乳腺癌、肝癌和结肠癌为肿瘤模型）（3）坏死性凋亡的分子调控机理

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Chen Y, Ren W, Wang Q, He Y, Ma D, Cai Z. The regulation of necroptosis by ubiquitylation. 2022, Apoptosis. 27(9-10):668-684 Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J, Chen J, Lian Z, Chen Y, Hu K, Chen Z, Cai Z, Liu M, Pang X. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer, 2022, J Clin Invest. 132(22): e161308. Wang X, Chen Y, Wang X, Tian H, Wang Y, Jin J, Shan Z, Liu Y, Cai Z, Tong X, Luan Y, Tan X, Luan B, Ge X, Ji H, Jiang X, Wang P. Stem cell factor SOX2 confers ferroptosis resistance in lung cancer via upregulation of SLC7A11. 2021, Cancer Res. canres.0567.2021. doi: 10.1158/0008-5472.CAN-21-0567 Lomphithak T, Akara-Amornthum P, Murakami K, Hashimoto M, Usubuchi H, Iwabuchi E, Unno M, Cai Z, Sasano H, Jitkaew S. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma. 2021, Sci Rep, 11(1):11743. Baik JY, Liu Z, Jiao D, Kwon HJ, Yan J, Kadigamuwa C, Choe M, Lake R, Kruhlak M, Tandon M, Cai Z, Choksi S, Liu ZG. ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer. 2021, Nat Commun, 12(1):2666 Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K, Feng J, Cai Z, Wei L, Liu M, Pang X. BCL6 confers KRAS-mutant non-small cell lung cancer resistance to BET inhibitors. 2021, J Clin Invest. 131(1):133090. Rui C, Shi S, Ren W, Qin X, Zhuang C, Chen X, Chen G, Yu J, Wang H, Cai Z. The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis. 2021, Biochem Pharmacol. 2;188:114542. Qin X?, Hu L?, Shi SN?, Chen X, Zhuang C, Zhang W, Jitkaew S, Pang X, Yu J, Tan YX#, Wang HY#, Cai Z#. The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases. 2020，Biochem Pharmacol. 177:113947. IF:4.825 Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y#, Liu M#, Pang X#. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. 2020，J Clin Invest，130(4):1752-1766. IF:12.282 石珅男, 蔡振宇等. 坏死性凋亡研究进展 [J]. 生物化学与生物物理进展, 2020,47(07):561-573. Qin X, Ma D, Tan Y#, Wang H#, Cai Z#. The role of necroptosis in cancer: a double-edged sword? 2019, Biochim Biophys Acta Rev Cancer, 1871:259-266. (#, Correspondence author) (Review) IF:8.220 Chen X?, Zhuang C?,#, Ren Y?, Zhang H, Qin X, Hu L, Fu J, Miao Z, Chai Y, Liu Z, Cai Z#, Wang H# , Identification of TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3, 2019, Br J Pharmacol, 176(12):2095-2108, (#, Correspondence author; ?, equal contribution) IF: 6.810 Zhang H?, Xu L?, Qin X?, Chen X, Cong H, Hu L, Miao Z, Zhang W#, Cai Z#, Zhuang C#. TAK-632 Analogues as Novel Necroptosis Inhibitors Selectively Targeting RIPK3: Synthesis, Structure-Activity Relationships and In Vivo Efficacy, 2019, J Med Chem, 62(14):6665-6681， (#, Correspondence author; ?, equal contribution) (Cover Story) IF: 6.253 Pan P, Cai Z, Zhuang C, Chen X, Chai Y. Methodology of drug screening and target identification for new necroptosis inhibitors, 2019, J Pharm Anal, 9(2):71-76. (Review) Cai Z, Liu Z. Detection of MLKL Oligomerization During Programmed Necrosis. 2018, Methods Mol Biol, 1857:85-92. (Book Chapter) Jiao D?, Cai Z?, Choksi S, Ma D, Choe M, Kwon H, Baik J, Rowan B, Liu C, Liu Z. Necroptosis of tumor cells leads to tumor necrosis and promotes tumor metastasis. 2018, Cell Research, 28(8):868-870. (?, equal contribution) IF: 15.393 Cai Z, Zhang A, Choksi S, Li W, Li T, Zhang X, and Liu Z. Activation of cell surface proteases promotes necroptosis, inflammation and cell migration. 2016, Cell Research, 26(8):886-900. IF: 15.393 Cai Z, Liu Z. Execution of RIPK3-regulated necrosis. 2014, Molecular & Cellular Oncology, 1:2, e960759. (Review) Cai Z?, Jitkaew S?, Zhao J?, Chiang H, Choksi S, Liu J, Ward E, Wu L, Liu Z. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol. 2014; 16(1):55-65. (?, equal contribution) (ESI Highly Cited Paper) IF: 19.064 Zhao J?, Jitkaew S?, Cai Z?, Choksi S, Li Q, Luo J, Liu ZG. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci U S A. 2012; 109(14):5322-7. (?, equal contribution) (ESI Highly Cited Paper) IF:9.504 Shi Z, Cai Z, Yu J, Zhang T, Zhao S, Smeds E, Zhang Q, Wang F, Zhao C, Fu S, Ghosh S, Zhang D. Toll-like receptor 11 (TLR11) prevents Salmonella penetration into the murine Peyer patches. J Biol Chem. 2012; 287(52):43417-23. IF: 4.011 Cai Z, Sancheza A, Shi Z, Zhang T, Liu M, Zhang D. Activation of Toll-Like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor Growth. Cancer Res. 2011; 71(7):2466-75. IF: 9.130 Shi Z, Cai Z, Sancheza A, Zhang T, Wen S, Wang J, Yang J, Fu S, Zhang D. A Novel Toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem. 2011; 286(6):4517-24. IF: 4.011 Cai Z, Shi Z, Sanchez A, Zhang T, Liu M, Yang J, Wang F, Zhang D. Transcriptional regulation of TLR11 gene expression in epithelial cells. J Biol Chem. 2009; 284(48):33088-96. IF: 4.011 Shi Z, Cai Z, Wen S, Chen C, Gendron C, Sanchez A, Patterson K, Fu S, Yang J, Wildman D, Finnell RH, Zhang D Transcriptional Regulation of the novel Toll-like receptor Tlr13. J Biol Chem. 2009; 284(31):20540-7. IF: 4.011 Cai Z, Zhang D. Toll-like receptor and cancer. Int J Genet. 2008; 31(4):275-281. Cai Z, Wang Y, Yu W, Xiao J, Li Y, Liu L, Zhu C, Tan K, Deng Y, Yuan W, Liu M, Wu X. hnulp1, a bHLH proteinwith a novel DUF654 domain, inhibits transcriptional activity of Serum Response Factor. Biochem Biophys Res Commun. 2006; 343(3):973-81. IF: 2.559 Ou Y, Wang S, Cai Z, Wang Y, Wang C, Li Y, Li F, Yuan W, Liu B, Wu X, Liu M. ZNF328, a novel human zinc-finger protein, suppresses transcriptional activities of SRE and AP-1. Biochem Biophys Res Commun. 2005; 333(3):1034-44 2. IF: 2.559 Wang Y, Li Y, Zeng W, Zhu C, Xiao J, Yuan W, Wang Y, Cai Z, Zhou J, Liu M, Wu X. IXL, a new subunit of the mammalian Mediator complex, functions as a transcriptional suppressor. Biochem Biophys Res Commun. 2004; 325(4):1330-8. IF: 2.559 蔡振宇. 第7章“心肌-内皮信号转导” ，《心脏发育研究》，湖南科学出版社, ISBN: 7-5357-3898-2 ，2004年2月, 蔡振宇, 袁婺洲, 吴秀山. 心肌-内皮信号途径在心脏发育中的作用, 2003, 生命科学研究. Vol. 7 No. 2 (Suppl.)